Treatment Options for Transplant-Ineligible Multiple Myeloma
Nina Shah, MD, discusses the current treatment options for treating patients with transplant-ineligible multiple myeloma.
Nina Shah, MD: For transplant-ineligible patients, we traditionally had been using things like bortezomib [Velcade], lenalidomide [Revlimid], and dexamethasone, or VRd light, with lenalidomide maintenance therapy and that’s a perfectly good combination to use. The most recent MAIA trial [NCT02252172] data that were presented at the European [Hematology Association] Congress really did solidify the role for daratumumab [Darzalex], lenalidomide, dexamethasone in patients who are transplant-ineligible because there’s both a PFS [progression-free survival] and an overall survival advantage. It sounds like there’s going to be some nice quality-of-life data to suggest that these people are doing better despite being on therapy for longer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
